Expenditures
|
Total expenditures
|
$1,887a,b
|
$1,360a
|
$1,341
|
(1,864-1,910)
|
(1,344-1,375)
|
(1,336-1,347)
|
Out-of-pocket expenditures
|
$148a,b
|
$546a
|
$570
|
(146–150)
|
(539–552)
|
(567–572)
|
Plan expendituresc
|
$1,708a,b
|
$822a
|
$776
|
(1,687-1,729)
|
(811–833)
|
(772–780)
|
Expenditures on brand name medications
| | | |
Total expenditures
|
$1,325a,b
|
$926a
|
$898
|
|
(1,305-1,346)
|
(911–941)
|
(893–903)
|
Out-of-pocket expenditures
|
$96a,b
|
$374a
|
$369
|
(94–98)
|
(368–381)
|
(367–371)
|
Plan expendituresc
|
$1,221a,b
|
$560a
|
$537
|
(1,202-1,240)
|
(549–571)
|
(533–540)
|
Expenditures exceeding the gap threshold
|
27.6%a,b
|
17.4%a
|
16.9%
|
(27.2-28.1)
|
(17.0-17.8)
|
(16.8-17.0)
|
Prescriptions
| | | |
Total number of prescriptions
|
38.1a,b
|
25.1a
|
26.5
|
(37.8-38.4)
|
(24.9-25.3)
|
(26.4-26.5)
|
Total number of brand name prescriptions
|
10.7a,b
|
6.4a
|
6.9
|
(10.5-10.8)
|
(6.3-6.5)
|
(6.87-6.92)
|
Adherence to medications
| | | |
Diabetes drug adherence
|
62.5%a,b
|
57.7%
|
57.4%
|
(61.0-63.9)
|
(56.0-59.4)
|
(56.9-58.0)
|
Hypertension drug adherence
|
65.6%a,b
|
64.2%a
|
62.4%
|
(64.9-66.3)
|
(63.5-64.9)
|
(62.2-62.6)
|
Lipid-lowering drug adherence
|
59.6%a,b
|
57.0%a
|
55.6%
|
(58.5-60.6)
|
(56.0-58.0)
|
(55.3-55.9)
|